Merck's Keytruda Qlex offers a groundbreaking subcutaneous cancer treatment, enhancing patient convenience with faster ...
The FDA has granted approval to subcutaneous Keytruda for use in adults and pediatric patients with a solid tumor.
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, ...
SurvivorNet on MSN
FDA Approves New Subcutaneous (Under-the-Skin) Option for Keytruda: What It Means for Cancer Patients
The U.S. Food and Drug Administration (FDA) has approved the subcutaneous form of Keytruda for a new 'Under-the-Skin' Option ...
Dr. Eric K. Singhi discusses the benefit of subcutaneous immunotherapy following the FDA approval of subcutaneous Opdivo for patients with solid tumors. On Dec. 27, 2024, the Food and Drug ...
– Late-breaking Phase III results show subcutaneous injection was non-inferior to intravenous infusion based on Ocrevus levels in the blood over 12 weeks – – Ocrevus subcutaneous injection was ...
The FDA has cleared the new version for across most of the solid tumour indications already granted for Keytruda, which is ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window MILAN -- An ...
Despite flat overall Q2 2025 sales, Keytruda's continued strong performance in oncology supports long-term bullish prospects ...
Most people know the feeling of getting a shot and having your arm feel sore for several days afterward. Some might even expect it as a side effect. The soreness happens when medications are injected ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback